hero-img.jpg

Combine COTELLIC with Zelboraf to achieve
powerful efficacy in patients with BRAF V600(+) metastatic melanoma1

Indication and dosing

Indication

COTELLIC® (cobimetinib) is indicated for use in combination with ZELBORAF® (vemurafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation